HCW Biologics (HCWB) Institutional Ownership $4.09 -0.25 (-5.76%) Closing price 08/15/2025 03:59 PM EasternExtended Trading$4.37 +0.28 (+6.85%) As of 08/15/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for HCW Biologics (NASDAQ:HCWB)CurrentInstitutional OwnershipPercentage2.96%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$39.60KNumber ofInstitutional Sellers(last 12 months)0 Get HCWB Insider Trade Alerts Want to know when executives and insiders are buying or selling HCW Biologics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data HCWB Institutional Buying and Selling by Quarter HCW Biologics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/6/2025 Golden State Wealth Management LLC10,000$40K0.0%N/A0.694% 5/2/2024 Pullen Investment Management LLC85,116$149K0.1%N/A0.225% 2/9/2024 Avantax Planning Partners Inc.179,541$220K0.0%N/A0.499% 2/9/2023 HighTower Advisors LLC269,869$517K0.0%+19.6%0.752% 11/15/2021 HighTower Advisors LLC14,000$45K0.0%N/A0.039% (Data available from 1/1/2016 forward) HCWB Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of HCWB shares? During the previous two years, the following institutional investors and hedge funds held shares of HCW Biologics shares: Avantax Planning Partners Inc. ($220K), and Pullen Investment Management LLC ($149K), Golden State Wealth Management LLC ($40K).Learn more on HCW Biologics' institutional investors. What percentage of HCW Biologics' stock is owned by institutional investors? 2.96% of HCW Biologics' stock is owned by institutional investors. Learn more on HCWB's institutional investor holdings. Which institutional investors have been buying HCW Biologics' stock? The following institutional investors have purchased HCW Biologics' stock in the last 24 months: Avantax Planning Partners Inc. ($179.54K), Pullen Investment Management LLC ($85.12K), and Golden State Wealth Management LLC ($10K). How much institutional buying is happening at HCW Biologics? Institutional investors have bought a total of 10,000 shares in the last 24 months. This purchase volume represents approximately $39.60K in transactions. Related Companies Dyadic International Institutional Ownership MIRA Pharmaceuticals Institutional Ownership NanoViricides Institutional Ownership Tenax Therapeutics Institutional Ownership FibroBiologics Institutional Ownership Natural Alternatives International Institutional Ownership Lisata Therapeutics Institutional Ownership Promis Neurosciences Institutional Ownership CASI Pharmaceuticals Institutional Ownership Reviva Pharmaceuticals Institutional Ownership This page (NASDAQ:HCWB) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HCW Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access